2026-04-06 · Consumer-facing medical device adverse event and recall accountability intelligence — automated manufacturer report cards, per-device safety scorecards, late-reporting surveillance, 510(k)-vs-PMA approval pathway risk analysis, Class I recall alerts, and weekly "Incident Report" dispatches that translate raw FDA MAUDE data into gorgeous, opinionated, name-and-shame data journalism. Not scare content. Evidence content.

Scar Tissue

The medical device industry doesn't want you to read this. Every adverse event, every recall, every late report — graded, graphed, and named.

💡 idea Total 15/20 Quality 4 Automation 4 Revenue 3 Complexity 4

Channel: Scar Tissue Tagline: The medical device industry doesn’t want you to read this. Every adverse event, every recall, every late report — graded, graphed, and named. Niche: Consumer-facing medical device adverse event and recall accountability intelligence — automated manufacturer report cards, per-device safety scorecards, late-reporting surveillance, 510(k)-vs-PMA approval pathway risk analysis, Class I recall alerts, and weekly “Incident Report” dispatches that translate raw FDA MAUDE data into gorgeous, opinionated, name-and-shame data journalism. Not scare content. Evidence content. Target audience: Patients with implanted or wearable medical devices (100M+ Americans), caregivers researching devices for family members, healthcare professionals tracking safety signals, medical device litigation attorneys, health journalists, patient advocates, biomedical engineers, and the 1.2-million-people-per-year whose adverse event reports were filed late by manufacturers and never knew it. Also: anyone who’s ever Googled “[device name] recall” or “is my [device] safe?” — a search pattern that generates millions of queries per year. Why now: A landmark BMJ study (March 2025) revealed that 1.2 million+ adverse event reports were filed late by device manufacturers — some years after patients were injured or killed. The FDA’s MAUDE database receives ~500,000+ reports per year, growing rapidly. The EU’s EUDAMED database is going public (2025-2026), enabling cross-jurisdiction transparency for the first time. Meanwhile, the 510(k) “substantially equivalent” clearance pathway — which lets devices reach market without clinical trials by claiming similarity to a predicate device — is under increasing scrutiny. ICIJ’s “Implant Files” investigation (2018) proved massive public interest, but it was a one-time project. Nobody is doing this continuously, automatically, with data-first rigor. The openFDA API makes all of this free and machine-readable.

Content Example:

Headline: Intuitive Surgical’s Stapler Problem Is Worse Than the Recall Suggests — A MAUDE Deep Dive

Incident Report #47 — April 2026

On March 19, 2026, Intuitive Surgical issued a Class II recall for its 8mm SureForm 30 curved-tip stapler reload cartridges after reports of four serious injuries and one death. The company described a manufacturing defect where staple legs could separate, causing tissue damage during robotic surgery.

That’s what the recall notice says. Here’s what the data says.

Scar Tissue pulled every MAUDE adverse event report mentioning Intuitive Surgical stapler systems filed in the last 36 months. The numbers tell a different story than a single recall notice:

By the numbers:

The predicate chain problem: The SureForm stapler system was cleared through the 510(k) pathway in 2018. Its predicate device? An earlier Intuitive stapler. That stapler’s predicate? A non-robotic Ethicon stapler from 2004. Three generations of “substantially equivalent” clearances — meaning no independent clinical trial data was required to put this device inside patients. The FDA never required Intuitive to prove the robotic stapler was safe. They only required Intuitive to show it was similar enough to a previous device. This is how the system works. This is the system.

Manufacturer Report Card — Intuitive Surgical (Q1 2026):

CategoryScoreDetail
Total MAUDE reports (12mo)🔴 1,847Top-10 device manufacturer by volume
Death reports (12mo)🟡 23Above median for surgical device makers
Late filing rate🟡 11.3%Industry average: ~9%
Active Class I recalls🟢 0No highest-severity recalls active
Active Class II recalls🔴 3Including the stapler reload
510(k) reliance🟡 87%High proportion of devices cleared without clinical trials
Overall GradeC+Below industry median for large-cap surgical device companies

What should patients do? If you have a robotic surgery scheduled using the da Vinci system with SureForm staplers, you deserve to ask your surgeon: “Are you using the recalled reload lot?” Your surgeon might not know — hospitals manage their own inventory. The recalled lots (listed below) cover cartridges distributed between October 2024 and February 2026. Print this page. Bring it to your pre-op appointment.

Sources: All data from openFDA Device Adverse Event API (MAUDE), openFDA Device Recall API, and FDA 510(k) clearance database. Methodology and raw query parameters published on our Transparency page. Scar Tissue does not provide medical advice.

Data Sources:

Automation Pipeline:

Tech Stack:

Monetization Model:

Launch Complexity: 3/5 — openFDA APIs are well-documented and generous. Main complexity is building the statistical analysis pipeline and the predicate chain graph builder. Astro static site is straightforward. Estimated: 2-3 weeks to MVP.

Content Quality Score: 5/5 — This is investigative data journalism powered by government transparency data. The BMJ study proving late reporting gives instant credibility anchor. Every claim sourced to a federal database. The “manufacturer report card” format is genuinely novel and useful.

Automation Score: 4/5 — Daily data collection fully automated. Weekly dispatch generation fully automated. Deep-dive articles on new Class I recalls need AI synthesis but can be templated. Only manual element: occasional editorial review of AI-generated narratives for sensitive death reports.

Revenue Potential: 5/5 — The legal professional audience alone is a goldmine. Lawyers pay $500/hour and spend weeks doing manual MAUDE research. A $29/mo tool that automates it is a no-brainer. Add consumer donations, premium newsletter, and the inevitable media citations (journalists will link to your manufacturer report cards), and this has strong multi-stream revenue.

Total: 17/20

Soul & Character:

Why This Will Work:

  1. The data is free, rich, and machine-readable — openFDA gives you 120K API calls/day for free. MAUDE alone has millions of records with structured fields plus narrative text for NLP analysis
  2. The ICIJ proved the demand — “Implant Files” was one of their most-read investigations. But it was a one-time project. This is the always-on version
  3. Long-tail SEO is massive — every device recall, every adverse event cluster, every manufacturer generates specific search queries. Thousands of auto-generated pages, each targeting real search intent
  4. The legal profession will pay — med-mal and mass tort attorneys need exactly this data, analyzed and presented. They currently pay consultants thousands for manual MAUDE analysis
  5. Trust through transparency — every claim links to the specific API query that produced it. Methodology page shows the code. This builds the kind of trust that generates donations
  6. Emotional resonance — these aren’t abstract statistics. Every death report in MAUDE is a person. The narrative excerpts are gut-wrenching. People share this content because it matters

Risk & Mitigation: